Provided is a compound of Formula 1

##STR00001##

wherein A.sup.1 is selected from CH.sub.2, CHR.sup.4, CR.sup.4R.sup.5, NH, NR.sup.4, O, or S; A.sup.2, A.sup.3, A.sup.4, and A.sup.5 are each independently selected from CH, CR.sup.6, or N; R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, when present, are independently hydrogen, hydroxy, acetyl, halo, carboxyl; a substituted or unsubstituted amino, alkyl, alkoxy, carboxyalkyl, alkylamide, acyl, acylamino aryl, arylalkyl, heteroalkyl, heteroalkoxy, heterocarboxyalkyl, heteroacyl, heteroacylamino, heteroaryl, or heteroarylalkyl; or a substituted or unsubstituted five-membered heterocycle where any member of the given ring may be C, N, O, or S.

Also provided is a method of treating a mammal undergoing an inflammatory disease, the method comprising administering the above compound to the mammal in a manner sufficient to reduce the severity of the inflammatory disease.

Proposed is a patch for the alleviation and prevention of acne, in which anti-acne activity of a biodegradable metal represented by Mg.sub.aZn.sub.bX.sub.c (in which a, b and c are wt % of individual components, a+b+c=100 wt %, 0≤a≤100, 0≤b≤100, and 0≤c≤10, among which a or b is the greatest, and X is at least one selected from the group consisting of Ca, Fe, Mn, Si, Na, Zr, Ce, and P) is demonstrated, thus exhibiting novel use thereof as a patch for the alleviation and prevention of acne.

A system and method for controlling medication-dispensing patches by a wearable device is provided. The method comprises receiving a transmission at a wearable device, wherein the transmission identifies a medication-dispensing patch; transmitting information corresponding to the identified medication-dispensing patch to an external computing device; receiving information at the wearable device from the external computing device, wherein the received information corresponds to a dosage of a medication that should be dispensed by the medication-dispensing patch; and transmitting information from the wearable device, wherein the transmission is configured for controlling a medication dosage that is dispensed by the medication-dispensing patch.

The present invention provides for an antiviral compound and analogues thereof for treatment or prevention of Flavivirus Dengue/Zika infections. In general the antiviral compound includes Eplerenone [pregn-4-ene-7, 21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo, γ-lactone, methyl ester (7α, 11α, 17α)] and its metabolites. Methods presented include treating Flavivirus infections, such as Zika virus, dengue virus, yellow fever virus and tick-borne encephalitis virus and Japanese encephalitis virus by administering the compound Eplerenone in therapeutically effective amounts and specific formulations as disclosed.

The present invention aims to provide a transdermal formulation in which apomorphine or a salt thereof is dissolved at a high concentration, so that a sufficient amount of apomorphine for treatment can be absorbed in a short time, and can be administered continuously.

The present invention can include, for example, a transdermal formulation, comprising apomorphine or a salt thereof, a polyhydric alcohol with a carbon number of 6 or less and/or a low molecular weight polyethylene glycol, and propylene carbonate.

According to the present invention, it is possible to prepare a solution containing apomorphine in a high concentration, and to allow a sufficient amount of apomorphine to be absorbed into the body through the skin in a short time and administered continuously.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

A pharmaceutical composition containing isomyosmine or a pharmaceutically acceptable salt thereof is administered to an individual in need thereof for treating a substance addiction, inclusive of affecting smoking substitution, eliminating cravings for tobacco and nicotine, or transitioning individuals away from smoking or the use of other tobacco products. In some examples, the therapeutic agent(s) are administered in a capsule, tablet, or lozenge. In other examples, the therapeutic agent(s) are administered via a chewing gum, inhalation spray, e-cigarette, nasal spray, or transdermal patch.

Provided are methods for selective extraction of cannabinoids, for example cannabidiol (CBD), from a plant source, by using tailored extraction media.

Disclosed are applications of a mussel adhesive protein or preparations thereof in suppression of skin inflammations. Specifically disclosed are applications of a mussel adhesive protein, preparations thereof and applications thereof in dermatitis, eczema, skin ulcer, technologies related to burns (comprising skin grafting), perniones, surgical incisions, herpes, abrasions, scars, psoriasis, erythema multiforme, skin damage after radiotherapy, skin cancers, folliculitis, urticaria and drug eruption, and applications in sunburn, polymorphous light eruption, pathological alopecia (comprising hair transplant), acne vulgaris, rosacea (that is, acne rosacea), and the like, and applications in the treatment of otitis externa.